Means and Methods for Treating Angiogenesis-Related Diseases
Endostatin is an antiangiogenic protein first discovered in Folkman's laboratory at Childrens Hospital, Harvard Medical School, and Boston. The antitumor properties of this pro-tein are well established. However, the amount of protein required for injection in pa-tients was beyond production feasibility due to the poor pharmacokinetics of endostatin mon-omer.
We have shown that the problem of poor pharmacokinetics can be solved by using the Fc domain of IgG being conjugated to en-dostatin, a component of all monoclonal anti-bodies approved for patients with a number of diseases including cancer. As a result of em-ploying Fc-endostatin, the half-life in mice was increased to 2 weeks instead of 2 hours for endostatin alone, consistent with pharmacoki-netics of monoclonal antibodies
Further Information: PDF
DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955
Contact
Dr. Ruth Herzog
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Recovering phosphorus from sewage sludge ash
Chemical and heat treatment of sewage sludge can recover phosphorus in a process that could help address the problem of diminishing supplies of phosphorus ores. Valuable supplies of phosphorus could…
Efficient, sustainable and cost-effective hybrid energy storage system for modern power grids
EU project HyFlow: Over three years of research, the consortium of the EU project HyFlow has successfully developed a highly efficient, sustainable, and cost-effective hybrid energy storage system (HESS) that…
After 25 years, researchers uncover genetic cause of rare neurological disease
Some families call it a trial of faith. Others just call it a curse. The progressive neurological disease known as spinocerebellar ataxia 4 (SCA4) is a rare condition, but its…